← Leaderboards
Balakrishna L. Lokeshwar
University Of Miami School Of Medicine
$5,068,178
Attributed
$5,690,678
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $629.3K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,690,678 · 5
VA$0 · 3
By mechanism
R01$5,680,678 · 4
R13$10,000 · 1
I01$0 · 2
IS1$0 · 1
Top collaborators
- Vinata B Lokeshwar2 shared
Most similar at University Of Miami School Of Medicine
Same institution · by research overlap
- Vinata B Lokeshwar$10,655,590
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsGrowthTumorMalignant - DescriptorIncidenceMalignant NeoplasmsRecurrenceKnock-OutUnited StatesTumor GrowthSignal TransductionProstateChemotherapyInvestigationXenograft ModelNeoplastic CellPathway InteractionsCell ProliferationPharmaceutical PreparationsIn VitroResistanceStagingMalignant Neoplasm Of ProstateAndrogens
Grant awards (31)
Glycosaminoglycan Targeting Treatment for Prostatic Hyperplasia and Fibrosis$615,750
R01 · FY2025 · DK
Glycosaminoglycan Targeting Treatment for Prostatic Hyperplasia and Fibrosis$629,250
R01 · FY2024 · DK
Role of B-arrestins in bladder cancer progression and response to chemotherapy$0
I01 · FY2023 · VA · contact PI
Role of B-arrestins in bladder cancer progression and response to chemotherapy$0
I01 · FY2021 · VA · contact PI
Role of B-arrestins in bladder cancer progression and response to chemotherapy$0
I01 · FY2020 · VA · contact PI
Role of B-arrestins in bladder cancer progression and response to chemotherapy$0
I01 · FY2019 · VA · contact PI
ShEEP Request for Plate Reader$0
IS1 · FY2019 · VA · contact PI
Role of B-arrestins in bladder cancer progression and response to chemotherapy$0
I01 · FY2018 · VA · contact PI
Chemoprevention of Prostate Cancer by Allspice Derived Polyphenol: Ericifolin$307,152
R01 · FY2016 · CA · contact PI
Chemoprevention of Prostate Cancer by Allspice Derived Polyphenol: Ericifolin$158,009
R01 · FY2015 · CA · contact PI
Chemoprevention of prostate cancer by Allspice derived polyphenol: Ericifolin$148,184
R01 · FY2015 · CA · contact PI
Role of chemokine Receptor CXCR7 in prostate cancer progression$0
I01 · FY2015 · VA · contact PI
Chemoprevention of prostate cancer by Allspice derived polyphenol: Ericifolin$312,599
R01 · FY2014 · CA · contact PI
Role of chemokine Receptor CXCR7 in prostate cancer progression$0
I01 · FY2014 · VA · contact PI
Chemoprevention of prostate cancer by Allspice derived polyphenol: Ericifolin$22,511
R01 · FY2013 · CA · contact PI
Role of chemokine Receptor CXCR7 in prostate cancer progression$0
I01 · FY2013 · VA · contact PI
Chemoprevention of prostate cancer by Allspice derived polyphenol: Ericifolin$317,475
R01 · FY2012 · CA · contact PI
Role of chemokine Receptor CXCR7 in prostate cancer progression$0
I01 · FY2012 · VA · contact PI
Chemoprevention of prostate cancer by Allspice derived polyphenol: Ericifolin$308,677
R01 · FY2011 · CA · contact PI
Antitumor and chemopreventive activity of the Ecuadorian plant extract BIRM$293,913
R01 · FY2010 · AT · contact PI
Antitumor and chemopreventive activity of the Ecuadorian plant extract BIRM$296,881
R01 · FY2009 · AT · contact PI
Antitumor and chemopreventive activity of the Ecuadorian plant extract BIRM$296,881
R01 · FY2008 · AT · contact PI
Antitumor and chemopreventive activity of the Ecuadorian plant extract BIRM$302,940
R01 · FY2007 · AT · contact PI
Control of the Metastatic Progression of Prostate cancer$258,895
R01 · FY2006 · CA · contact PI
Control of the Metastatic Progression of Prostate cancer$265,125
R01 · FY2005 · CA
Control of the Metastatic Progression of Prostate cancer$265,125
R01 · FY2004 · CA
Control of the Metastatic Progression of Prostate cancer$265,125
R01 · FY2003 · CA
CONTROL OF METASTATIC PROGRESSION OF PROSTATE CANCER$209,672
R01 · FY2002 · CA
CONTROL OF METASTATIC PROGRESSION OF PROSTATE CANCER$205,197
R01 · FY2001 · CA
Non Antibiotic Properties of Tetracycline$10,000
R13 · FY2001 · CA
CONTROL OF METASTATIC PROGRESSION OF PROSTATE CANCER$201,317
R01 · FY2000 · CA